BM

Braskem Takes Polypropylene to the Next Level of Performance in Partnership with WEAV3D® utilizing its Rebar for Plastics® Lattice Technology

Retrieved on: 
Thursday, September 28, 2023
Recycling, Chemicals, Plastics, Automotive Manufacturing, Environment, Sustainability, Manufacturing, Other Manufacturing, Carbon, SPE, Plastic, Climate, BM, Business development, Original equipment manufacturer, BAK, Society of Plastics Engineers, Multimedia, Steel, Carbon footprint, Keynote, PP, Role, Conference, NYSE, Biopolymer, Wood-plastic composite, Renewable energy, Braskem

View the full release here: https://www.businesswire.com/news/home/20230928754765/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230928754765/en/
    The WEAV3D lattice technology enables lightweight PP parts to replace materials like steel, increasing PP’s use in automotive applications by balancing improvements in performance, weight, and cost.
  • The combination of Braskem PP sheets with WEAV3D’s Rebar for Plastics will allow Braskem to compete in new structural material end-markets.
  • “We’re excited to offer our clients new innovations and partnerships around high-performance polypropylene materials utilizing the WEAV3D lattice technology.
  • As the automotive industry continues to roll out new electric vehicle designs, it requires automakers to re-think the vehicle design with cutting-edge performance materials.

AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics

Retrieved on: 
Monday, September 25, 2023
Frontotemporal dementia, Asos, BM, PIKFYVE, Human, Therapy, Head, Survival, Innovation, MBA, UNC13A, Doctor of Philosophy, DSM-IV codes, Science, Paul Auguste Hariot, Shi, Dementia, Patient, Amyotrophy, Master of Science, ASO, Government, IND, FTD, MRCP, Pharmaceutical industry, Takeda, ALS

MONROVIA, Calif., Sept. 25, 2023 /PRNewswire/ -- AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced today that it has entered into a license agreement with Takeda to develop and commercialize AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Key Points: 
  • AcuraStem's therapeutic strategy for PIKFYVE focuses on addressing neurodegeneration by expelling toxic protein aggregates and protecting healthy neuronal function.
  • Under the terms of the agreement, Takeda will receive an exclusive, worldwide license to AcuraStem's PIKFYVE program.
  • "I'm very pleased that AcuraStem is partnering with Takeda around their PIKFYVE program," said Justin Ichida, PhD.
  • Destum Partners acted as transaction advisor to AcuraStem, and Foley Hoag acted as legal counsel to AcuraStem.

Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval

Retrieved on: 
Thursday, September 21, 2023
MESO, BM, Partnership, EAP, GVHD, Blood, Code, Marketing, Expanded access, Survival, CFR, Title 21 of the Code of Federal Regulations, Type, Patient, Steroid, Prochymal, MSB, FDA, Transplant, Inflammation, Dietary supplement, Pharmaceutical industry, Mesoblast

FDA clarified that the key remaining issue for pediatric approval is providing further evidence that the potency assay will assure the consistent efficacy of commercial product.

Key Points: 
  • FDA clarified that the key remaining issue for pediatric approval is providing further evidence that the potency assay will assure the consistent efficacy of commercial product.
  • The key outcomes of the meeting and Mesoblast next steps are:
    Mesoblast summarised the large body of existing clinical data with the improved RYONCIL® product version of remestemcel-L, manufactured after 2008 using the current process inspected by FDA, for potential approval in children.
  • Mesoblast presented clinical data indicating that RYONCIL was associated with much higher survival of children with SR-aGVHD in the Expanded Access Protocol (EAP) compared with the earlier Prochymal version manufactured before 2008.
  • Mesoblast expects to receive the formal minutes of the Type A meeting within three weeks.

Parexel Appoints Gwyn Bebb, BM, BCh., Ph.D., to Lead Oncology Clinical Development

Retrieved on: 
Tuesday, September 19, 2023
Amgen, BM, Clinical trials unit, POET, Drug development, University, Tom Baker Cancer Centre, Head, Cancer, Research, Department of Medicine – University of Pamplona, Lung, Natural science, Patient, ChromeOS, Nursing, Medical imaging, Parexel

In this role Dr. Bebb will lead the research and development of new cancer treatments for biopharmaceutical customers worldwide.

Key Points: 
  • In this role Dr. Bebb will lead the research and development of new cancer treatments for biopharmaceutical customers worldwide.
  • “The complexities of oncology require agile, multifaceted teams to push the boundaries of drug development and deliver groundbreaking treatment options for patients with cancer,” said Amy McKee, M.D., Chief Medical Officer and Head, Oncology Center of Excellence.
  • Most recently he was a Clinical Research Medical Director at Amgen in both early- and late-stage oncology drug development where he shepherded a biphasic T cell engager to a confirmational Phase III trial.
  • His experience also includes clinical practice as a Medical Oncologist focused on lung and gastrointestinal cancers.

Braskem’s Carbon Negative Biopolymers to Be Spotlighted by “World’s Greatest…!” Television Series

Retrieved on: 
Monday, September 11, 2023
TV and Radio, Manufacturing, Environmental Health, General Entertainment, Entertainment, Agriculture, Natural Resources, Green Technology, Environment, Sustainability, Chemicals, Plastics, BM, PE, Food, Drink, Carbon footprint, Biotechnology, BAK, Mohawk Innovative Technology, GHG, Multimedia, Recycling, Carbon, History, Technology Center, Hygiene, Amazon, I&T, Greenhouse gas, Climate change, Ecosystem, Polyethylene, NYSE, Bloomberg Television, Renewable energy, Braskem

Braskem was selected to participate in the series given the company’s investment in creating a carbon-neutral circular economy and its commitment to creating groundbreaking, sustainable products as a result.

Key Points: 
  • Braskem was selected to participate in the series given the company’s investment in creating a carbon-neutral circular economy and its commitment to creating groundbreaking, sustainable products as a result.
  • “We are honored to have been selected to be spotlighted by the “World’s Greatest…!” television series,” said Walmir Soller, VP of Olefins and Polyolefins, at Braskem Europe & Asia.
  • For every ton of I’m green™ bio-based PE produced, it removes 3.09 tons of carbon from the atmosphere.
  • By 2030, we seek to reduce scope 1 and 2 greenhouse gas emissions by 15%; and to achieve carbon neutrality by 2050.

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

Retrieved on: 
Thursday, August 31, 2023
MESO, BM, SR, Regenerative Medicine Advanced Therapy, Research and development, Blood, FINANCIAL, STI, Marketing, Clinical trial, International University of Management and Administration, Degenerative disc disease, Research, LVAD, CMO, Mesoblast, EDT, Pain, Administration, Data analysis, Patient, Survival, Heart, Pivotal, Mortality, Ageing, MSB, Transplant, FDA, BLA, US FDA, Inflammation, Rare-earth element, Pharmaceutical industry, Cryptocurrency, Palladium, Vaccine, Renewable energy, Fine chemical, Takeda, LTI – Lingua Tertii Imperii

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones.

Key Points: 
  • NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones.
  • Net cash usage for operating activities was US$63.3 million for FY2023, a 37% reduction compared with FY2021 and 4% reduction compared with FY2022.
  • DETAILS OF FINANCIAL RESULTS FOR THE PERIOD ENDED JUNE 30, 2023 (FY2023)
    Research & Development expenses reduced by US$5.6 million (17%), down to US$27.2 million for FY2023 compared to US$32.8 million for FY2022.
  • It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2023/
    The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com

Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development

Retrieved on: 
Thursday, August 17, 2023
KRON, BM, IPO, Cancer, SAN, Corporate development, Management

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company.
  • The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.
  • “During his tenure, Yasir made tremendous contributions to Kronos Bio,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
  • I’m confident that Kronos Bio is well positioned for success with its innovative science, near-term data milestones and seasoned leadership team.”

GERDAU S.A. - CONSOLIDATED INFORMATION

Retrieved on: 
Wednesday, August 9, 2023
CVM, Tax, Depreciation, BM, BRL, Security (finance), EBITDA, Investment, NYSE, GGB, Indian stock exchange, Bookkeeping

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), reaching R$ 3.8 billion, with an adjusted EBITDA margin of 20.8%.

Key Points: 
  • Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), reaching R$ 3.8 billion, with an adjusted EBITDA margin of 20.8%.
  • Adjusted EBITDA from the North America Business Operation reaches R$1.8 billion, with an adjusted EBITDA margin of 26.1%, in the second quarter.
  • Gerdau (NYSE: GGB, BM&Fbovespa: GGBR3, GGBR4) will invest BRL 3.2 billion between 2023 and 2026 in a new sustainable mining platform in Minas Gerais.
  • Gerdau S.A. informs that it is filling today its 2Q23 results at the Securities and Exchange Commission (SEC) and at the Comissão de Valores Mobiliários (CVM), which are available at Gerdau's website.

Trio Petroleum Corp Announces Commencement of Full Field Development Activities of its South Salinas Project

Retrieved on: 
Friday, July 7, 2023
Well, Trio, BM, Week, Perforation, Product testing, NYSE, Acquisition, Water, Project, Union Avenue, Rare-earth element

DANVILLE, CA, July 07, 2023 (GLOBE NEWSWIRE) -- Trio Petroleum Corp (NYSE American: TPET) (“Trio” or the “Company”), a California-based oil and gas company, today announced that it has commenced activities for the Full Field Development of its South Salinas Project (“Project”). The services of an independent, third-party consulting firm have been engaged to expand the existing Initial Environmental Impact Report (IEIR) into a Full Environmental Impact Report (FEIR) and to obtain conditional use permits and other permits that are necessary for the Full Field Development of the Project. This firm has prior experience and expertise at the Project and was instrumental in generating the IEIR and in obtaining Trio’s existing permits for the HV-1, HV-2, HV-3A and HV-4 wells.

Key Points: 
  • Scheduled Production Test for HV-1 Discovery Well Set for the Week of July 10, 2023
    DANVILLE, CA, July 07, 2023 (GLOBE NEWSWIRE) -- Trio Petroleum Corp (NYSE American: TPET) (“Trio” or the “Company”), a California-based oil and gas company, today announced that it has commenced activities for the Full Field Development of its South Salinas Project (“Project”).
  • This firm has prior experience and expertise at the Project and was instrumental in generating the IEIR and in obtaining Trio’s existing permits for the HV-1, HV-2, HV-3A and HV-4 wells.
  • The consulting firm will assist and play a key role in obtaining the Full Field Development Permit.
  • CEO Frank Ingriselli stated: “We are thrilled to embark on the commencement of Full Field Development activities for our South Salinas Project, marking an exciting milestone for Trio.

The Future is Here: 3nm ASIC Technology in Cryptocurrency Miners

Retrieved on: 
Thursday, June 15, 2023
Miner, BM, Silicon, CMO, Rest, Mining, ASIC, Cryptocurrency

These 3 nanometer ASIC miners have been tipped by many experts as the future of crypto mining.

Key Points: 
  • These 3 nanometer ASIC miners have been tipped by many experts as the future of crypto mining.
  • The immense power of Bitmanu’s BM1, BM2, and BM Pro miners have made them most powerful and profitable mining rigs ever.
  • Powered by the latest and most advanced silicon semiconductor chips, Bitmanu miners offer higher transistor density, better mining speed, and reduced power consumption.
  • Unlike most other products in the market, Bitmanu miners are extremely energy-efficient in spite of their extraordinary processing powers.